238 related articles for article (PubMed ID: 10456482)
1. Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions.
Bonnabry P; Sievering J; Leemann T; Dayer P
Eur J Clin Pharmacol; 1999 Jul; 55(5):341-7. PubMed ID: 10456482
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
Gibbs MA; Thummel KE; Shen DD; Kunze KL
Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
[TBL] [Abstract][Full Text] [Related]
3. [Q-DIPS: current approach to prediction of drug interactions].
Leemann T; Dayer P
Schweiz Med Wochenschr; 1992 Dec; 122(50):1930-2. PubMed ID: 1465597
[TBL] [Abstract][Full Text] [Related]
4. Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies.
Bonnabry P; Sievering J; Leemann T; Dayer P
Clin Pharmacokinet; 2001; 40(9):631-40. PubMed ID: 11605713
[TBL] [Abstract][Full Text] [Related]
5. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
6. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
Clin Pharmacokinet; 2000 Feb; 38(2):111-80. PubMed ID: 10709776
[TBL] [Abstract][Full Text] [Related]
7. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
8. Factors confounding the successful extrapolation of in vitro CYP3A inhibition information to the in vivo condition.
Wienkers LC
Eur J Pharm Sci; 2002 Apr; 15(3):239-42. PubMed ID: 11923055
[TBL] [Abstract][Full Text] [Related]
9. Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats.
Kishimoto W; Takano J; Senda C; Ishiguro N; Sakai K; Igarashi T
Biol Pharm Bull; 2000 Sep; 23(9):1027-32. PubMed ID: 10993198
[TBL] [Abstract][Full Text] [Related]
10. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
Lu C; Hatsis P; Berg C; Lee FW; Balani SK
Drug Metab Dispos; 2008 Jul; 36(7):1255-60. PubMed ID: 18381489
[TBL] [Abstract][Full Text] [Related]
11. [Drug-drug interaction of antifungal drugs].
Niwa T; Shiraga T; Takagi A
Yakugaku Zasshi; 2005 Oct; 125(10):795-805. PubMed ID: 16205037
[TBL] [Abstract][Full Text] [Related]
12. Modulation of irinotecan metabolism by ketoconazole.
Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
[TBL] [Abstract][Full Text] [Related]
13. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes.
Nielsen TL; Rasmussen BB; Flinois JP; Beaune P; Brosen K
J Pharmacol Exp Ther; 1999 Apr; 289(1):31-7. PubMed ID: 10086984
[TBL] [Abstract][Full Text] [Related]
14. Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo.
Lane HY; Chiu CC; Kazmi Y; Desai H; Lam YW; Jann MW; Chang WH
Drug Metabol Drug Interact; 2001; 18(3-4):263-78. PubMed ID: 11791889
[TBL] [Abstract][Full Text] [Related]
15. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 isozymes and antiepileptic drug interactions.
Levy RH
Epilepsia; 1995; 36 Suppl 5():S8-13. PubMed ID: 8806399
[TBL] [Abstract][Full Text] [Related]
17. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
Li A; Yeo K; Welty D; Rong H
Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole.
Paine MF; Schmiedlin-Ren P; Watkins PB
Drug Metab Dispos; 1999 Mar; 27(3):360-4. PubMed ID: 10064566
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general.
Boxenbaum H
J Pharm Pharm Sci; 1999; 2(2):47-52. PubMed ID: 10952769
[TBL] [Abstract][Full Text] [Related]
20. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
